• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    GoodRx Appoints Raj Beri as Chief Operating Officer, Mark Hull as Chief Product Officer and Vina Leite as Chief People Officer

    5/9/22 8:30:00 AM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email

    The company bolsters its leadership team with experienced mission-driven executives

    GoodRx (NASDAQ:GDRX), a leading consumer-focused digital healthcare platform, today announced it has made key leadership appointments to support the company's scaling business and accelerate innovation to bring more affordable and convenient healthcare to consumers across the country.

    Raj Beri will join GoodRx as the company's first ever Chief Operating Officer (COO) from Uber, where he served as Vice President of Grocery and New Verticals, overseeing the company's non-restaurant and last mile delivery businesses across global markets. With more than 20 years in the business operations space, Raj will lead continued growth and expansion at GoodRx, while helping increase value across the prescriptions business.

    "GoodRx has seen tremendous growth over the past few years and I am eager to help lead the company through the next phase of its evolution as part of this innovative leadership team," said Beri. "I'm passionate about working on audacious problems across sectors that are ripe for disruption, and GoodRx is at the center of that disruption in the healthcare industry."

    In addition, Mark Hull has been named the first ever Chief Product Officer to help the company build industry-leading solutions for consumers, providers and pharmacists. Previously a senior product executive at Meta and LinkedIn, Mark will draw on his more than 25 years of experience in the product management industry to make GoodRx more accessible, convenient and useful for consumers, while helping scale opportunities with partners.

    Vina Leite has joined GoodRx as the company's first Chief People Officer. With expertise in the global human resources and talent management space, Vina brings more than two decades of experience in transforming high-growth and Fortune 500 organizations. Vina will support growth at GoodRx by helping to develop scalable people operations functions while hiring and developing top talent in an environment that is empowered by diversity, equity and inclusion.

    The company also welcomes Scott Paul as Senior Vice President of Healthcare & Consumer Innovation. Scott will leverage his substantial healthcare experience and knowledge to work with senior leadership on all areas of healthcare innovation across the ecosystem of consumers, retailers, PBMs, providers and drug manufacturers. Scott previously founded Apex Affinity, where he created and ran many of the largest pharmacy discount programs in the market, and most recently served as Executive Vice President at MedImpact, where he focused primarily on consumer savings and digital health.

    "As GoodRx continues on our rapid growth trajectory, we're thrilled to welcome these mission-driven additions to our leadership team," said Doug Hirsch, co-CEO and co-founder of GoodRx. "Raj, Mark, Vina and Scott are innovative, forward-thinking executives who believe in GoodRx's vision and core values. Their deep experience and expertise across consumer-driven, B2B and healthcare industries will be invaluable to GoodRx as we continue to help millions of consumers access affordable and convenient healthcare."

    Andrew Slutsky will transition to a new role at the company, driving new initiatives as Senior Vice President of Strategy & Marketing Innovation.

    About GoodRx

    GoodRx is a leading consumer-focused digital healthcare platform. Our technology delivers strong savings, trusted information and access to care to make healthcare affordable and convenient for all Americans. Since 2011, we have helped consumers save over $35 billion and are one of the most downloaded medical apps over the past decade.

    Forward-Looking Statement

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future operations, growth and financial results and the benefits of new hires. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the satisfaction of the closing conditions of the vitaCare acquisition, risks associated with acquired businesses, including risks related to our limited operating history and early stage of growth; our ability to achieve broad market education and change consumer purchasing habits; our ability to continue to attract, acquire and retain consumers in a cost-effective manner; our reliance on our prescription transactions offering and ability to expand our offerings; changes in medication pricing and pricing structures; our inability to control the categories and types of prescriptions for which we can offer savings or discounted prices; our reliance on a limited number of industry participants; the competitive nature of industry; our ability to attract, develop, motivate and retain well-qualified employees; and the other important factors discussed under the caption "Risk Factors" in GoodRx's Annual Report on Form 10-K for the year ended December 31, 2021, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005308/en/

    Get the next $GDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    2/27/2026Overweight → Neutral
    Analyst
    1/22/2026$2.75Buy → Hold
    Jefferies
    12/9/2025$3.00Underweight
    Barclays
    8/11/2025Strong Buy → Outperform
    Raymond James
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoodRx downgraded by Analyst

    Analyst downgraded GoodRx from Overweight to Neutral

    2/27/26 8:28:37 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx downgraded by Jefferies with a new price target

    Jefferies downgraded GoodRx from Buy to Hold and set a new price target of $2.75

    1/22/26 8:25:34 AM ET
    $GDRX
    EDP Services
    Technology

    Barclays initiated coverage on GoodRx with a new price target

    Barclays initiated coverage of GoodRx with a rating of Underweight and set a new price target of $3.00

    12/9/25 8:49:54 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rey-Giraud Agnes exercised 192,185 shares at a strike of $0.47, gifted 75,219 shares and received a gift of 75,219 shares, increasing direct ownership by 313% to 352,852 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    3/13/26 7:22:26 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Nabiey Romin converted options into 12,434 shares and covered exercise/tax liability with 5,121 shares, increasing direct ownership by 4% to 183,061 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    3/9/26 5:19:20 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 4 filed by Officer Mcginnis Christopher A

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    3/5/26 8:11:56 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/30/23 4:41:35 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/17/23 7:08:30 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $GDRX
    SEC Filings

    View All

    GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications

    Collaboration expands access to trusted therapies with discounted cash prices for leading brands including Lipitor®, Celebrex®, Viagra®, and Norvasc® GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established brand medications more affordable for consumers. Beginning today, eligible commercially insured patients may pay as low as $0–$4 on select Viatris medications through GoodRx. Cash-paying consumers, regardless of insurance status, can use GoodRx to access discounted cash prices of up to 85% off at more than 70,000 pharmacies nationwide. The collaboration i

    3/11/26 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen®

    GoodRx Employer Direct enables self-insured employers to subsidize the $449 Lilly Employer Connect medication price for Zepbound KwikPen to reduce employee out-of-pocket costs Brief Summary: GoodRx to collaborate with Eli Lilly to expand employer-sponsored access to Zepbound® KwikPen®, an FDA-approved dual GIP and GLP-1 obesity treatment Through GoodRx Employer Direct, self-insured employers can subsidize Lilly's $449 discounted medication price for Zepbound KwikPen Employer contributions are applied to the medication cost, reducing employee out-of-pocket costs GoodRx integrates manufacturer discounted pricing and employer funding in real time; optional telemedicine supports p

    3/6/26 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Expands Into Employer Market With Launch of "GoodRx Employer Direct"

    New program combines employer-subsidized discounted cash prices and custom telemedicine solutions with existing health benefits to close coverage gaps and support access to high-impact medications GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced the launch of GoodRx Employer Direct. The new offering enables employers to directly lower the cost of high-impact brand medications, including GLP-1s, by applying targeted subsidies to discounted cash prices from pharmaceutical manufacturers. Employers can also deploy branded versions of GoodRx's condition-specific telemedicine solutions, integrating clinical care, prescribing, and pharmacy fulfillm

    2/24/26 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    3/27/26 4:19:53 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by GoodRx Holdings Inc.

    SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    3/27/26 9:31:05 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    3/18/26 4:59:09 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Financials

    Live finance-specific insights

    View All

    GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its fourth quarter and full year 2025 financial results after U.S. markets close on Wednesday, February 25, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, February 26, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live

    1/28/26 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Third Quarter 2025 Results

    Company Maintains Full Year 2025 Revenue and Adjusted EBITDA Expectations; Raises Pharma Manufacturer Solutions Revenue Outlook to Approximately 35% Year-Over-Year Growth for 2025 GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the third quarter of 2025. Third Quarter 2025 Highlights Revenue of $196.0 million Net income of $1.1 million; Net income margin of 0.6% Adjusted Net Income1 of $28.8 million; Adjusted Net Income Margin1 of 14.7% Adjusted EBITDA1 of $66.3 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of

    11/4/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025. GoodRx management will also hold a conference call and webcast the following morning, Wednesday, November 5, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To participate via telephone, please call (800) 715-9871 at least 10 minutes before the conference call is scheduled to begin. The conference ID is 9085550. The call will also be webcast live on the Company's investor relat

    10/8/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/14/24 12:29:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/13/24 4:30:24 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/12/24 4:02:41 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Leadership Updates

    Live Leadership Updates

    View All

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    3/17/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology